Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Design Therapeutics, Inc.DSGN · Entity 4991 | Chief Accounting Officer | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Design Therapeutics, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2036-01-01 | Direct | 150,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 150,000 · Balance 150,000 F1: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2027, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2027, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 21:11 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001883722-26-000002 · form4-01052026_090130.xml · derivative · entry 1 Burgess Julie · CIK 0001883722 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2027, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. Read SEC document |
| January 02, 2025 Filed Jan 7, 2025 00:00 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock option (right to buy) · Derivative | 135,000 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0001415889-25-000879 · form4-01062025_070130.xml · derivative · entry 1 Burgess Julie · CIK 0001883722 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2026, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 21:41 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-24-001042 · doc4.xml · derivative · entry 1 Burgess Julie · CIK 0001883722 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: The shares subject to the option will vest as follows: 20% of the shares will vest on January 1, 2025, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:43 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $7.97 | $0.00 |
DisclosureSEC source: 0001209191-23-006927 · doc4.xml · derivative · entry 1 Burgess Julie · CIK 0001883722 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: The shares subject to the option will vest as follows: 20% of the shares will vest on February 1, 2024, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 00:49 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $12.77 | $0.00 |
DisclosureSEC source: 0001209191-22-006576 · doc4.xml · derivative · entry 1 Burgess Julie · CIK 0001883722 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: The shares subject to the option will vest as follows: 20% of the shares will vest on February 1, 2023, 20% of the shares will vest in equal monthly installments over the following 12 months, 30% of the shares will vest in equal monthly installments over the following 12 months, and 30% of the shares will vest in equal monthly installments over the following 12 months. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 20:53 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 135,000 | $0.00 Strike: $14.99 | $0.00 |
DisclosureSEC source: 0001209191-21-059038 · doc4.xml · derivative · entry 1 Burgess Julie · CIK 0001883722 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2031-09-30 F1 · derivative.exercise_date: 25% of the shares vest one year after September 13, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.